Decision-Making Structure Determines Success in Technology Licensing

Biocatalyst Search Limited, a UK-based executive search firm, conducted in-depth interviews with 19 Chief Business Officers (CBOs) and Chief Executive Officers (CEOs) from biotech companies to analyze organizational bottlenecks in deal execution. The key finding is that scientific merit alone does not guarantee a licensing agreement; rather, the CEO, CBO, and Board of Directors must reach a consensus on asset valuation, scope of rights, and minimum acceptable terms, which ultimately determines negotiating power. The interviews repeatedly addressed role clarity, board alignment, the CEO's approach to negotiation, and the gap between responsibility and authority. This analysis examines business development governance, applicable from preclinical to late-stage clinical assets, and is not limited to studies evaluating a single drug or clinical trial result.

Board Alignment is Necessary During Strategy Formulation, Not Just Before Contract Signing

If the Board renegotiates regional rights, co-development options, or economic lower limits after the term sheet is presented, it can simultaneously damage deal speed and erode trust with the counterparty. Therefore, companies should define priorities for cash needs, acceptable upfront payments, conditional milestones, royalties, and equity investments on a scenario-by-scenario basis before engaging with potential partners. Assigning negotiating responsibility to the CBO while limiting their approval authority can lead to repeated internal re-approvals during negotiations. Designating a portion of the Board as a deal advisory group can provide real-time insights into management's cash runway and long-term asset value assessment.

CEO Involvement and CBO Role Define Pricing

If the CEO intervenes directly in negotiations without prior agreement, it can disrupt the price buffer and sequence of concessions that the CBO has established. Conversely, the CEO can convey the overall vision and strategic rationale, while the CBO manages competitive bidding, rights design, and economic terms, creating a coordinated approach that delivers a consistent message to the other party. The CBO's role is also expanding beyond contract signing to encompass portfolio prioritization, capital raising, and market assessment, becoming a strategic partner. Separating equity financing, typically handled by the CFO, from the CBO's licensing activities can make it difficult to optimize the timing of dilution and the transfer of asset rights.

Governance's Economic Value is Increasing in the Large Deal Market

According to IQVIA, the global biopharmaceutical licensing deal value in 2025 is expected to reach USD 232 billion, the highest in a decade, making internal decision-making speed a direct competitive factor. The 2025 SSGJ-707 agreement between Pfizer (PFE) and 3SBio (01530.HK) serves as a comparative example, involving an upfront payment of USD 1.25 billion, an equity investment of USD 100 million, potential milestones exceeding USD 4.8 billion, and tiered double-digit royalties for the rights to a PD-1/VEGF bispecific antibody outside of China. SSGJ-707 is a clinical trial code name without a brand name, and Pfizer stated that it will prioritize global Phase 3 development for non-small cell lung cancer and other solid tumors. In such complex deals, whether the CEO, CBO, and Board have pre-agreed on regional rights and conditional payments is a more accurate indicator of actual value captured than the total reported amount.